A Study of Safety, Pharmacokinetics, Pharmacodynamics of JNJ-61610588 in Participants With Advanced Cancer
Status:
Terminated
Trial end date:
2017-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and tolerability of JNJ-61610588 in
participants with advanced cancer in order to determine a recommended Phase 2 dose (RP2D) for
further evaluation in specific tumor types.